anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention relates to novel cross-linkers for hydrogels, in particular for hyaluronan hydrogels, corresponding hydrogels including said cross-linkers and various applications thereof. The cross linker of the invention is a bi- or multifunctional cross-linker comprising or consisting of an aromatic or heteroaromatic ring system with 3-6 C atoms which is coupled via functional groups on at least 2 ring positions with at least 2 terminal groups capable to form a covalent bond with thiol or amino groups, in particular with thiol groups in a thiol-en reaction. The cross-linker may be charged or uncharged. In a specific embodiment, the terminal groups are coupled to carboxy groups of the aromatic or heteroaromatic ring system via an ester or amide bond. More specifically, the cross-linker of the invention is a derivative of pyridine-3, 5-dicarboxylic acid or a corresponding pyridinium salt thereof wherein 2 terminal groups are coupled to the carboxy groups of the pyridine or pyridinium core via an ester or amide bond. In a preferred embodiment, the cross-linker is N 3 ,N 5 -bis(2-acrylamidoethyl) pyridine-3, 5-dicarboxamide or a 3,5-bis((2-acrylamidoethyl) carbamoyl) -1-methylpyridin-l-ium-halogenide.
The initial dosing of the nafamostat mesilate group is 0.5mg/kg/h. We maintain ACT at 180\~220s by adjusting the dosage of nafamostat mesilate.
Orthostatic hypotension and syncope have been reported with therapeutic doses of duloxetine. Syncope and orthostatic hypotension tend to occur within the first week of therapy but can occur at any time during duloxetine treatment, particularly after dose increases. The risk of blood pressure decreases may be greater in patients taking concomitant medications that induce orthostatic hypotension (such as antihypertensives) or are potent CYP1A2 inhibitors [see and ] and in patients taking duloxetine at doses above 60 mg daily. Consideration should be given to discontinuing duloxetine in patients who experience symptomatic orthostatic hypotension and/or syncope during duloxetine therapy. Orthostatic hypotension and syncope have been reported with therapeutic doses of duloxetine. Syncope and orthostatic hypotension tend to occur within the first week of therapy but can occur at any time during duloxetine treatment, particularly after dose increases. The risk of blood pressure decreases may be greater in patients taking concomitant medications that induce orthostatic hypotension (such as antihypertensives) or are potent CYP1A2 inhibitors [see Warnings and Precautions ( 5.12)  and Drug Interactions ( 7.1) ] and in patients taking duloxetine at doses above 60 mg daily. Consideration should be given to discontinuing duloxetine in patients who experience symptomatic orthostatic hypotension and/or syncope during duloxetine therapy.
FIELD: medicine.SUBSTANCE: invention refers to medicine, namely to oncology, haematology and cardiology, and can be used for managing patients with chronic myeloid leukaemia in prescribing tyrosine kinase inhibitors (TKI). Cardiovascular system is examined, and a ten-year risk of cardiovascular mortality is assessed by the SCORE scale. Prior to prescribing the treatment, it is necessary to determine presence or absence of ischemic heart disease (IHD) in the patient. If there is no ischemic heart disease with low and medium SCORE risk, the patient is prescribed one of the following preparations: imatinib, dasatinib, nilotinib, bosutinib, ponotinib, after which once in 3 months: the patient is examined by a hematologist, the patient is biochemically analyzed for total cholesterol, a lipid spectrum, glucose, B-type natriuretic peptide, NT-proBNP, troponins, electrocardiography, echocardiography, bicycle ergometry, control of arterial pressure. Dascplerography of the brachiocephalic trunk is performed once in 6 months. If nilotinib is prescribed, the patient is examined by a haematologist and all the above-mentioned studies, except for ultrasonic Doppler sonography of the brachiocephalic trunk, should be performed once a month, and ultrasonic Doppler sonography of the brachiocephalic trunk once in 3 months. If observing no adverse events, the patient is required to be examined by a therapist and cardiologist once every 6 months. If observing the adverse events, the therapist and the cardiologist are examined once a month, reducing frequency to 1 every 6 months with the elimination of the adverse events. If the patient has a high and very high SCORE risk in the absence or presence of IHD, he is prescribed one of the following preparations: imanitib, dasatinib, bozutinib. Thereafter, once a month: a patient is examined by a hematologist, the patient is examined biochemically for total cholesterol, a lipid spectrum, glucose, B-type natriuretic peptide, NT-proBNP, troponins, electrocardiography, echocardiography, bicycle ergometry, control of arterial pressure. Doppler sonography of the brachiocephalic trunk is performed once in 3 months. If observing no adverse events, the patient is examined by a therapist and cardiologist once every 3 months. If observing the undesirable events, the patient is examined by the therapist and cardiologist once a month, reducing the frequency of adverse events by 1 time in 6 months.EFFECT: method provides preventing the development of IHD in the patients with chronic myeloid leukaemia when prescribing TKI, as a result of the use of a clear scheme of prescribing any TKI, monitoring the occurrence of adverse events, determining the order of examination of the patient in case of adverse events.1 cl, 4 ex
BACKGROUND: Progressive supranuclear palsy (PSP) is a rare neurodegenerative disease characterized by the accumulation of aggregated tau proteins in astrocytes, neurons, and oligodendrocytes. Previous genome-wide association studies for PSP were based on genotype array, therefore, were inadequate for the analysis of rare variants as well as larger mutations, such as small insertions/deletions (indels) and structural variants (SVs).
METHOD: In this study, we performed whole genome sequencing (WGS) and conducted association analysis for single nucleotide variants (SNVs), indels, and SVs, in a cohort of 1,718 cases and 2,944 controls of European ancestry. Of the 1,718 PSP individuals, 1,441 were autopsy-confirmed and 277 were clinically diagnosed.
RESULTS: Our analysis of common SNVs and indels confirmed known genetic loci at MAPT, MOBP, STX6, SLCO1A2, DUSP10, and SP1, and further uncovered novel signals in APOE, FCHO1/MAP1S, KIF13A, TRIM24, TNXB, and ELOVL1. Notably, in contrast to Alzheimer's disease (AD), we observed the APOE ε2 allele to be the risk allele in PSP. Analysis of rare SNVs and indels identified significant association in ZNF592 and further gene network analysis identified a module of neuronal genes dysregulated in PSP. Moreover, seven common SVs associated with PSP were observed in the H1/H2 haplotype region (17q21.31) and other loci, including IGH, PCMT1, CYP2A13, and SMCP. In the H1/H2 haplotype region, there is a burden of rare deletions and duplications (P = 6.73 × 10-3) in PSP.
CONCLUSIONS: Through WGS, we significantly enhanced our understanding of the genetic basis of PSP, providing new targets for exploring disease mechanisms and therapeutic interventions.
<P>PROBLEM TO BE SOLVED: To find an effective component utilized for a food and a health food or the like, from a horse chestnut seed coat of a so-called food remainder part which is not served for usual eating.  <P>SOLUTION: A polyphenol is obtained by extracting the horse chestnut seed coat of an object to be wasted, by means of hot water treatment, alkaline solution immersion treatment, and boiling with an alkaline solution or the like. The polyphenol has a structure of flavan-3-ol as a basic structure. It is guessed that the basic structure is related to an interflavan bonding and is polymerized. The polymerized polyphenol has antioxidizing action and oxygen inhibition action or the like and is added to the food of the health food or the like.  <P>COPYRIGHT: (C)2010,JPO&INPIT
PURPOSE: Although recurrence risk is a major concern for women having had an ischemic stroke (IS) and who are planning a pregnancy, studies on recurrence risk and pregnancy outcomes are scarce and heterogeneous.
METHODS: This retrospective study assessed women aged 15-44 years with a diagnosis of ischemic stroke admitted in the Lyon Stroke Centre, France, between January 2009 and December 2013. The primary outcome was stroke recurrence during pregnancy or the post-partum period. Secondary outcomes were pregnancy complications.
RESULTS: Overall, 104 women with a prior ischemic stroke were included. Mean age at the time of the stroke was 36 ± 6.7 years old. Stroke etiology was large-artery atherosclerosis for 1 woman, cardioembolism for 23 women, and undetermined for 55 women. No antiphospholipid syndrome was found. Among them, 29 women had 58 subsequent pregnancies. Overall, there were three IS recurrence (2.9%), but none occurred during pregnancy. There were 27 miscarriages (47% of pregnancies), two pre-eclampsia (3%), and one stillbirth (1.7%).
CONCLUSIONS: We observed no recurrence of IS during pregnancy. The study also highlighted that the risk of miscarriages was higher than general population and that of stillbirth should be further studied.
Clinical studies of Ganciclovir Injection did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. Ganciclovir Injection is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because renal clearance decreases with age, Ganciclovir Injection should be administered to elderly patients with special consideration of their renal status. Renal function should be monitored and dosage adjustments should be made accordingly Clinical studies of Ganciclovir Injection did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. Ganciclovir Injection is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because renal clearance decreases with age, Ganciclovir Injection should be administered to elderly patients with special consideration of their renal status. Renal function should be monitored and dosage adjustments should be made accordingly [see Dosage and Administration (2.5), Warnings and Precautions (5.2), Use in Specific Populations (8.6)] .
Obesity is usually treated as a medical disease, prescribing interventions which adhere to the theoretically sound principles.The prevalence of obesity is increasing, and, accordingly, an increasing number of morbidly obese patients are eligible for Bariatric Surgery. This surgical procedure is highly effective and is often followed by resolution or remission of obesity related comorbidities (e.g. diabetes and obstructive sleep apnea). However, some individuals may have psychological and motivational problems that reduce these beneficial effects. Bariatric surgery represents a substantial part of total health care costs, and such costs may increase in the future. Another issue is that it is important to prevent post-surgical relapses. Hence, there is every reason to increase the effect and efficacy of both conservative treatments and bariatric surgery.

Clinically the investigators meet patients who regain their weight post-surgically, and the investigators have some experience that these patients may display more dysfunctional eating than those who are able to maintain a lower target weight. Given the expected outcome of the RCT, the autonomous motivation for lifestyle changes will be increased. Lowering dysfunctional eating, as well as increasing the probability of better success in preoperative weight loss, may help the patient to maintain a healthier weight after the surgical procedure. Moreover, developing a more tailored intervention for surgery patients may enable new evidence based treatments to be established for these patients.
Managing anticoagulant therapy in patients with comorbidities such as kidney disease, liver disease, obesity, thrombophilia and increased bleeding risk with thrombocytopenia presents unique challenges. Renal impairment affects drug clearance. Liver disease alters coagulation and drug metabolism. Obesity affects drug distribution and dosing. Increased bleeding risk with thrombocytopenia often requires different dosing. This review finds that tailored therapeutic strategies are essential to balance the risks and benefits in these complex patient populations.
This is a group intervention (10-15 participants) that consists of 5 weekly sessions lasting 2 hours. In our protocol, we added 3 more final sessions of 2 hours in order to emphasize the practices, specially in self-compassion, resulting in 8 weeks of intervention.
NEW MATERIAL:The compound of formula I [R1 and R2 are H or lower alkoxy; A is single bond, lower alkylene or lower alkenylene; R3 and R4 are lower alkyl or R3 and R4 together form lower alkylene; R5 is -X-(CO)n-Y (X is single bond, lower alkylene, etc.; n is 0 or 1; Y is H, cycloalkyl, aryl, etc.), etc.]. EXAMPLE:4-[4-( Carbamoylmethyl )piperidinocarbonylmethyl]phenyl 4-guanidino benzoate dihydrochloride. USE:It has the activity of proteolytic enzyme and is useful for the remedy of pancreatitis, thrombotic syndrome, etc. PREPARATION:The compound of formula I can be produced by carrying out dehydrative condensation of p-nitrobenzoic acid of formula II with the compound of formula III, reducing the resultant compound of formula IV to convert the nitro group to amino group and guanidinating the product.
<P>PROBLEM TO BE SOLVED: To provide a means for detecting infection with Pseudomonas aeruginosa.  <P>SOLUTION: A nucleotide has a DNA sequence indicated by sequence number 1 (refer to the specification) and encodes an outer membrane protein F (OMPF) of the Pseudomonas aeruginosa. A fragment thereof encodes an immunogenic polypeptide toxic to E. coli cells. A protein and a polypeptide are encoded with the nucleotide and nucleotide fragment. An antibody against them is provided. A diagnostic aid and a composition containing them are provided.  <P>COPYRIGHT: (C)2004,JPO
Women aged 18 and over with urinary incontinence will be taken. A total of two online interviews will be conducted with women in the control group, one of which is a pre-test interview and one is a final interview where post-tests are applied.
Participants will receive tips to foster self-efficacy and skills training around infant safety. Participants will receive daily text messages for 12 weeks. Twice a week participants will be asked to self-monitor their adherence to safety goals in response to a text messaging prompt and will immediately receive tailored feedback and tips.
Patients in corticosteroid group will receive systemic corticosteroid. In case of severe, the patients may receive methylprednisolone (no more than 1 gram/day) followed by gradual taper of oral prednisone.
Everolimus has immunosuppressive properties and may predispose patients to bacterial, fungal, viral, or protozoal infections, including infections with opportunistic pathogens [see Adverse Reactions (6.1)]. Localized and systemic infections, including pneumonia, mycobacterial infections, other bacterial infections, invasive fungal infections (e.g., aspergillosis, candidiasis, or PJP) and viral infections (e.g., reactivation of hepatitis B virus) have occurred. Some of these infections have been severe (e.g., sepsis, septic shock, or resulting in multisystem organ failure) or fatal. The incidence of Grade 3 and 4 infections was up to 10% and up to 3%, respectively. The incidence of serious infections was reported at a higher frequency in patients < 6 years of age [see Use in Specific Populations (8.4)]. 

Complete treatment of preexisting invasive fungal infections prior to starting treatment. Monitor for signs and symptoms of infection. Withhold or permanently discontinue everolimus based on severity of infection [see Dosage and Administration (2.9)]. 

Administer prophylaxis for PJP when concomitant use of corticosteroids or other immunosuppressive agents are required.
Participants received QVA149 plus placebo to tiotropium during 1 of 3 treatment periods, once a day for 6 weeks. Participants were provided with a salbutamol/albuterol inhaler to use as rescue medication.
The Awareness, Courage and Love intervention will consist of a single 120-minute online session delivered in a group format via a videoconferencing application (e.g., Zoom). The theme of the session will evolve around "making friends and being seen" to reinforce the appetitive functions of social connection.
Oral Naldebain 37.5 mg (0.5 mL oil solution) + SafeTynadol 650 mg + Tween 20 and PEG 400 (1 capsule), multiple doses for 3 days. Dosing at 0（2 ± 2 hour after surgery）, 6 ± 2, 14 ± 2, 22 ± 2, 34 ± 2, 46 ± 2, 58 ± 2 and 70 ± 25 hours after the first dose.
Cardioembolic stroke accounts for over 20% of ischemic strokes and is associated with worse outcomes than other types of strokes. Atrial fibrillation (AF) is the most common risk factor for cardioembolic stroke. In this narrative review, we present an update about cardioembolic stroke mainly related to AF and atrial cardiopathy. Direct oral anticoagulants (DOACs) have revolutionized stroke prevention in patients with AF; however, their efficacy in preventing recurrent embolic stroke of unknown source remains uncertain. Various cardiac monitoring methods are used to detect AF, which is crucial for preventing stroke recurrence. DOACs are preferred over warfarin for AF-related stroke prevention; however, the timing of initiation after acute ischemic stroke is debated. Resuming anticoagulation after intracerebral hemorrhage in AF patients requires careful assessment of the risks. While catheter ablation may reduce the incidence of cardiovascular events, its effect on stroke prevention is unclear, especially in heart failure patients. Atrial cardiopathy is the emerging cause of embolic stroke of unknown source, which indicates atrial structural and functional disorders that can precede AF. Future research should focus on refining stroke risk prediction models, optimizing AF detection, understanding the roles of ablation and anticoagulation in stroke prevention, and establishing atrial cardiopathy as a therapeutic target, which could significantly reduce the burden of stroke.
Midazolam 3 mg, orally, once on Day 1, followed by brigatinib 90 mg, orally, once daily on Days 2 to 8, further followed by brigatinib 180 mg, orally, once daily on Days 9 to 28 in Part A Cycle 1 (28 days treatment cycle). Participants escalating to brigatinib 180 mg once daily will also receive midazolam 3 mg, orally, once on Day 21 of Part A Cycle 1. After completion of Part A, participants will continue into Part B. Participants in Part B will receive brigatinib up to 180 mg (or at the highest tolerated dose in Part A), orally, once daily in a 28 day treatment cycle, up to a maximum of 23 cycles or until progression of disease, unacceptable toxicity, or another discontinuation criterion is met.
A device for providing nicotine replacement therapy may be provided. The device may comprise a processor. The processor may be configured to perform one or more actions. A cessation program for a user may be determined. A program intervention event based on a phase of the cessation program may be determined. A marker associated with the user may be determined. A modification to the cessation program may be determined based on the program intervention event.
Add three hours of intense physical activities per week to baseline activities. Weekly exercise should include at least 30 minutes of strength building activities and at least two hours of aerobic activities. Exercise bouts lasting 20 min or longer will be counted with respect to total weekly training time.
Hypoxia-inducible factors -1 (HIF-1) is a crucial transcription factor that regulates the expression of glycolytic genes. Our previous study proved that the Mud crab dicistrovirus-1 (MCDV-1) can induce aerobic glycolysis that favors viral replication in mud crab Scylla paramamosain. However, the role of HIF-1 on key glycolytic genes during the MCDV-1 infection has not been examined. In this study, the intricate interplay between HIF-1 and the key glycolysis enzyme, lactate dehydrogenase (LDH), was investigated after MCDV-1 infection. The expression of LDH was significant increased after MCDV-1 infection. Additionally, the expression of HIF-1α was upregulated following MCDV-1 infection, potentially attributed to the downregulation of prolyl hydroxylase domains 2 expression. Subsequent examination of the SpLDH promoter identified the presence of hypoxia response elements (HREs), serving as binding sites for HIF-1α. Intriguingly, experimental evidence demonstrated that SpHIF-1α actively promotes SpLDH transcription through these HREs. To further elucidate the functional significance of SpHIF-1α, targeted silencing was employed, resulting in a substantial reduction in SpLDH expression, activity, and lactate concentrations in MCDV-1-infected mud crabs. Notably, SpHIF-1α-silenced mud crabs exhibited higher survival rates and lower viral loads in hepatopancreas tissues following MCDV-1 infection. These results highlight the critical role of SpHIF-1α in MCDV-1 pathogenesis by regulating LDH gene dynamics, providing valuable insights into the molecular mechanisms underlying the virus-host interaction.